QSS
CBIO

Quantitative Systematic Strategies’s Crescent Biopharma CBIO Stock Holding History

Quantitative Systematic Strategies’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-208
Closed -$197K – 495
2018
Q4 		$197K Buy
208
+63
+43% +$75.8K 0.04% 530
2018
Q3 		$209K Sell
145
-19
-12% -$28.7K 0.04% 516
2018
Q2 		$264K Buy
+164
New +$282K 0.05% 496

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Quantitative Systematic Strategies's CBIO Position: Q1 2019 in Review

Quantitative Systematic Strategies sold out of Crescent Biopharma (CBIO) in Q1 2019, closing a stake of 208 shares — an estimated $197K sold.

Quantitative Systematic Strategies first reported a position in CBIO in Q2 2018 and held it in 3 quarters. The position peaked at $264K in Q2 2018. 77 funds tracked by Wall St. Rank hold CBIO as of Q1 2019.

  • Quantitative Systematic Strategies reported no remaining Crescent Biopharma position as of Q1 2019 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 208 Crescent Biopharma shares in Q1 2019, an estimated $197K.
  • Quantitative Systematic Strategies first reported a position in Crescent Biopharma in Q2 2018 and held it in 3 quarters.
  • Quantitative Systematic Strategies's Crescent Biopharma position peaked at $264K in Q2 2018.
  • 77 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2019.

Based on Quantitative Systematic Strategies's 13F filing for Q1 2019, filed 15 Apr 2019.